Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $103.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 29.78% to $103.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $488.0 million, a 4.31% decrease, with the full-year FY2025 number at $488.0 million, down 4.31% from a year prior.
  • Change in Acquisitions & Divestments was $103.9 million for Q4 2025 at Kymera Therapeutics, down from $132.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $147.9 million in Q4 2024 to a low of $60.5 million in Q1 2021.
  • A 5-year average of $109.5 million and a median of $105.2 million in 2022 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 490.74% in 2021, then plummeted 32.6% in 2023.
  • Kymera Therapeutics' Change in Acquisitions & Divestments stood at $96.9 million in 2021, then rose by 1.1% to $97.9 million in 2022, then fell by 22.32% to $76.1 million in 2023, then surged by 94.43% to $147.9 million in 2024, then fell by 29.78% to $103.9 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Change in Acquisitions & Divestments are $103.9 million (Q4 2025), $132.4 million (Q3 2025), and $119.0 million (Q2 2025).